Latest United States Startup Funding Rounds
Startup funding in United States: recent rounds, the companies behind them and their participating investors.
- Rounds
- 2,225 Jan 1 – Oct 26, 2026
- Disclosed funding
- $250.8B 1847 disclosed amounts
- Median round
- $24M Of disclosed amounts
| Company | Amount | Round | Sector | Country | Investors | Announced |
|---|---|---|---|---|---|---|
| CI Cast InsightsCompany profile A real-time spoken intelligence platform that converts public speech into structured, real-time insights A real-time spoken intelligence platform that converts public speech into structured, real-time insights | $4.5M | Pre-SeedPre-seed | AI | United States | Investors | |
| W WorkstreetCompany profile Workstreet provides AI-native cybersecurity and compliance services to regulated industries Workstreet provides AI-native cybersecurity and compliance services to regulated industries | Undisclosed | Growth | Cybersecurity | United States | Investors | |
| P PaperCompany profile Design platform for the agentic era, enabling designers and engineers to collaborate through a shared language. Design platform for the agentic era, enabling designers and engineers to collaborate through a shared language. | $34M | Series A | AI | United States | Investors | |
| WF Developer and manufacturer of advanced solid oxide fuel cell systems. | Undisclosed | Undisclosed | Climate tech | United States | Investors Undisclosed | |
 AbstractCompany profile Streaming security operations that detect threats in motion and route data across an organisation’s tools. Streaming security operations that detect threats in motion and route data across an organisation’s tools. | $25M | Undisclosed | Cybersecurity | United States | Investors | |
| CH Automates the financial infrastructure of American healthcare | $120M | Series DSeries C+ | Healthtech | United States | Investors | |
| TB Transcripta BioCompany profile AI-powered drug discovery company developing treatments for neurological and neuromuscular diseases AI-powered drug discovery company developing treatments for neurological and neuromuscular diseases | $24M | Series A | Biotech | United States | Investors | |
| P PawPay turns any policy into pet insurance that pays vet directly | Undisclosed | Undisclosed | Fintech | United States | Investors | |
| CT Crystalys TherapeuticsCompany profile Crystalys Therapeutics develops dotinurad, an oral URAT1 inhibitor for treating gout Crystalys Therapeutics develops dotinurad, an oral URAT1 inhibitor for treating gout | $130M | Series B | Biotech | United States | Investors | |
| NB N-Zyme BiomedicalCompany profile Developing first-in-class therapies targeting pepsin for reflux disease Developing first-in-class therapies targeting pepsin for reflux disease | $4.6M | Series A | Biotech | United States | Investors Undisclosed |
Active investors in this selection
All investors →Ranked by rounds participated in · From Jan 1, 2026
- 1Y Combinator (YC)
BioStack, Tractian, Blacksmith
132rounds3led - 2Andreessen Horowitz (a16z)
ASI, Eka Robotics, Town
99rounds20led - 3General Catalyst
Provision Labs, Tractian, Different
70rounds7led - 4Alumni Ventures
Maxinsights, Daytona, Chariot Claims
60rounds0led - 5Khosla Ventures
Arda Industries, Tolan
58rounds6led
Latest digests
Archive →Explore published rounds while the next edition is being prepared.